NY-MEDICREA
The Medicrea Group (Euronext Growth Paris: FR0004178572 – ALMED, PEA-PME eligible, and OTCQX: MNRTY and MNRTF), pioneering the transformation of spinal surgeries through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI (Adaptive Spine Intelligence) technology, announced today that the Company is attending the Eurospine 2018 meeting taking place in Barcelona, Spain, from September 19th to 21st , where UNiD™ LAB biomedical engineers will showcase the most recent developments of the Company’s UNiD™ ASI technology.
Denys Sournac, President and Chief Executive Officer, stated, “At Eurospine 2018, our team of biomedical engineers will show attending spine surgeons how the UNiD™ASI technology answers the gap left by traditional implant manufacturers through a demonstration of the UNiD™ HUB, a software platform that fully integrates surgical planning through machine learning to generate personalized implants that are adapted to each individual patient and at the same time to each individual surgeon technique.”
Five years after its initial launch in September 2013, over 2,800 patients have benefited from UNiD™ ASI 100% proprietary pre-operative planning technologies and services associated with patient-specific spinal realignment rods, with a strong acceleration in adoption rate in 2018 (+60% cases in year-to-date 2018) especially in the USA.
Since its inception, the technology supported surgeons specializing in adult indications with planning services and patient-specific implants focused on restoring sagittal alignment. More recently, surgeons have found the technology to be fully applicable to the pediatric population as well. As such, surgeons have increasingly published on the application of UNiD™ ASI in pediatrics and have begun to demonstrate the importance of respecting sagittal parameters in the pediatric population.
Jean-Luc Clément, M.D. of Fondation Lenval (Nice, FRANCE) and UNiD™ASI user recently published the Article titled “Surgical Increase of Thoracic Kyphosis Increases Unfused Lumbar Lordosis in Selective Fusion for Thoracic Adolescent Idiopathic Scoliosis” . In this article, Jean-Luc Clément emphasizes “...the importance of restoring adequate kyphosis and respecting the links between sagittal parameters (thoracic kyphosis, lumbar lordosis and pelvic incidence) specifically in adolescent surgery. A task which is close to impossible for a surgeon without the appropriate tools that are now provided by Medicrea through UNID™ ASI Platform. Data analytics and predictive modeling are topics that surgeons and healthcare professionals recognize will shape the future of care and the way we view spine surgery.”
The recent publication by Jean-Luc Clément, M.D. et al. hypothesizes that correction of hypokyphosis in AIS increases lumbar lordosis, especially its proximal part by reciprocal changes. The study involves 111 patients selectively instrumented using the ST2R technique on the thoracic region with 2 years of follow-up. The author demonstrates and evaluates that non-instrumented lumbar lordosis was directly increased and proportionally impacted by the thoracic kyphosis correction.
Jean-Luc Clément also stated, “These results are supporting the use of the UNiD™ ASI platform to obtain the expected patient-specific thoracic kyphosis to adapt lumbar lordosis to the patient’s specific pelvic incidence.”
Medicrea’s proprietary UNiD™ ASI technology and services integrates numerous proprietary predictive models, one of which takes into consideration the post-operative compensatory mechanisms occurring on the non-instrumented portion of the spine both above and below the construct. Through the UNiD™ HUB, the algorithms use large amounts of data to generate intelligent surgical planning through machine learning while simultaneously allowing the surgeon to perform detailed, custom analysis of the cases. Medicrea uses proprietary data science to drive improved outcomes and economic efficiencies in spine surgery.
Meeting attendees are invited to learn more about Medicrea at Booth 33B.
About Medicrea (www.medicrea.com)
Through the lens of predictive medicine, Medicrea leverages its proprietary software analysis tools with big data and machine learning technologies supported by an expansive collection of clinical and scientific data. The Company is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.
Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 200 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D- printed titanium patient-specific implants.
For further information, please visit: Medicrea.com.
Connect with Medicrea
FACEBOOK
| INSTAGRAM
| TWITTER
| WEBSITE
| YOUTUBE
Medicrea
is listed on
EURONEXT Growth Paris
ISIN:
FR 0004178572
Ticker:
ALMED
LEI:
969500BR1CPTYMTJBA37
Medicrea is traded on
OTCQX Best Market
Tickers:
MNRTY & MRNTF
View source version on businesswire.com: https://www.businesswire.com/news/home/20180920005476/en/
Contact:
Medicrea Denys Sournac Founder, Chairman and CEO dsournac@medicrea.com or Fabrice Kilfiger, +33 (0)4 72 01 87 87 Chief Financial Officer fkilfiger@medicrea.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Université Paris-Saclay and Owkin: A Unique Alliance to Propel University Medical Research to the Top of the European Rankings Through AI20.11.2025 15:17:00 CET | Press release
Université Paris-Saclay and Owkin announce the signing of a memorandum of understanding to explore the potential of K Pro Free - Owkin’s AI co-pilot for biology - for use by Paris-Saclay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120130113/en/ K Pro Free will now be available to the entire Université Paris-Saclay community, and in particular teachers, researchers and doctoral students working in the biomedical sciences. The partnership includes workshops, training sessions and events designed to promote the discovery and adoption of K Pro Free, as well as the co-organization of communication and dissemination initiatives around the use of AI in health. In this way, the partnership will promote user training, but also enrich and continuously improve the co-pilot's models through feedback and use cases from the l’Université Paris-Saclay community. This partnership is part of Université Paris-Saclay’s strategy to integr
Frasca Advances Flight Training Technology with New Visual System Powered by Unreal Engine20.11.2025 15:05:00 CET | Press release
Frasca International, Inc., a FlightSafety International company and leader in flight simulation, today announced the launch of VITAL FVS 100, the next evolution of its visual system technology. Building on the proven TruVision Global platform, VITAL FVS 100 was developed using Epic Games’ Unreal Engine and delivers unprecedented realism, scalability, and innovation in pilot training. The Unreal-powered VITAL FVS 100 system introduces major advancements in visual fidelity and training realism, further enhancing the capabilities of Frasca, a leading developer of flight simulators and training devices. The new system includes physically based renderings, advanced lighting effects, and a new volumetric cloud model that creates dynamic, weather-rich environments. Terrain imagery now includes one-meter resolution coverage for the contiguous United States and Hawaii, with expanded global datasets covering European buildings and tree covered regions. Additionally, enhanced particle effects re
GigaOm Radar for Vector Databases v3 Positions Vespa.ai as a Leader and Outperformer20.11.2025 15:00:00 CET | Press release
Vespa Recognized for Integrated Ranking, Multimodal Search, and Production-Scale AI Performance Vespa.ai, the creator of the AI Search Platform for building and deploying large-scale, real-time AI applications powered by big data, today announced its recognition as a Leader and Outperformer in the GigaOm Radar for Vector Databases v3, marking the company’s third consecutive year being evaluated in GigaOm’s vector database research. Now in its third edition, the report compares 17 leading open source and commercial solutions using GigaOm’s structured evaluation framework. In addition to core table-stakes capabilities, the Radar reviews each vendor’s key features, emerging strengths, and broader business criteria. The shift from Sonar to Radar reflects the technology’s transition into mainstream adoption. GigaOm names Vespa.ai a leader for its ability to manage complex data, optimize results at scale, and support multimodal AI workloads. The report highlights Vespa’s native tensor suppor
Hitit Empowers Airlines to Optimize Crew Leave Planning with Gurobi20.11.2025 15:00:00 CET | Press release
With Crane Crew, one of the products in Hitit’s Crane Solution Suite, dozens of airlines have reduced their planning periods from weeks to minutes. Gurobi Optimization, LLC, the leader in decision intelligence technology, is proud to be the solver of choice for Hitit, a leading global provider of airline and travel IT solutions. Hitit’s Crane Crew Leave Optimizer—one of the key sub-modules of Hitit’s Crane Crew solution—enables airlines to quickly generate optimal leave schedules for thousands of crew members. Powered by Gurobi’s mathematical optimization solver, the tool significantly reduces planning time while improving both operational efficiency and crew satisfaction. Among the many constraints that airlines must consider are operational requirements, business rules, crew seniority, and personal preferences. As such, manual planning efforts can often lead to inefficiencies, crew dissatisfaction, and compliance risks. After switching to Crane Crew, Hitit’s partner airlines have rep
Myonex Appoints Greg Lavin as Chief Executive Officer20.11.2025 15:00:00 CET | Press release
Greg Lavin takes over the CEO role as James Lovett retires and joins the company’s Board of Directors Myonex®, a leading global integrated clinical trial supply solutions and commercial services company, announced today that Greg Lavin, Chief Financial Officer (CFO), will assume the role of Chief Executive Officer (CEO) effective January 1, 2026. A seasoned executive with experience in the pharmaceutical services industry, including senior roles across clinical research organizations, preclinical and laboratory services, and healthcare data analysis, Lavin succeeds James Lovett, who is retiring and will remain on the company’s board of directors to provide strategic guidance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120250133/en/ Greg Lavin at Myonex's Headquarters in Horsham, PA During his 6-plus years as CFO of Myonex, Lavin has worked closely with Lovett in driving its transformation from a comparator sourcing su
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom